DJ and ex-election candidate reveals ‘valuable life lesson' he learned after month in hospital
'I spent 60 years of my life feeling well, so to suddenly face multiple problems at once feels completely alien to me'
DJ and former election candidate Niall Boylan has revealed how he 'learned a valuable life lesson' having spent nearly a month in hospital.
The 'shock jock' who had left his Classic Hits radio show, Nighttime Talks to run in the European Elections last year, told fans he was 'recovering slowly'.
Without referring to the reason why he ended up in hospital, he did say that over the last five months he had 'been unwell'.
'At one point, I was very ill and spent nearly a month in hospital,' he posted on X. 'My wife has been by my side and my support through it all.
Why am I telling you this? Because I've learned a valuable life lesson.'
He said the lesson he had learned was that 'many of those you thought cared about you couldn't give a s**t, and many people you least expected turned out to care the most.'.
'The other lesson is, don't always trust the medical profession. In my case, they had no idea what was wrong with me, even after literally hundreds of blood tests, CT scans, and ultrasounds, until I demanded certain specific blood tests (long story), and I was right.'
He added: 'Thankfully, I'm recovering, but it's a slow process and hard to deal with. I spent 60 years of my life feeling well, so to suddenly face multiple problems at once feels completely alien to me.
'You do wonder if you'll ever normal again.'
Last year, Boylan described his run for Europe as 'an experience of a lifetime' although he ultimately fell short, earning 50,416 votes.
He also ruled out a general election run despite having 'no doubt' he would be elected after just narrowly missing out on an MEP seat.
He laughed off the suggestion of launching a presidential run as he is 'very opinionated' and also ruled out running for European election again in five years' time.
'It was an amazing experience – and I kept the Green Party out. I was happy that I kind of upset the political establishment because I made it more difficult. There was about 50,000 votes that I took away from Fine Gael and Fianna Fáil. If I hadn't been there, they may have got the quota quicker.'
Boylan, who feels there should be stronger curbs on immigration into Ireland and believes people are sick of 'woke culture', said he knows some people view him as an extremist but denies that is the case.
'People think I'm some sort of radical right-winger, I'm not. I voted yes to marriage equality.'
He said he did feel that the EU was too left-wing.
'I think for far too long it's been far too left. I think that's going to change and you're going to see a shift slightly to the centre. I don't want to see a radical extreme right-wing Europe either.'
Boylan added that got a lot of abuse online during the campaign because of his outspoken views.
'I've been a pretty loud outspoken voice for 30 years on radio and I tend not to care what other people think of what I say. I'm not politically correct and I want to be a loud voice for people in Dublin and Ireland in Europe
'There was some really nasty stuff put up about me online, most of it, 99.99 percent, completely untrue. Some of it was derogatory and defamatory.
'I didn't react to it. You just can't have that kind of stuff knocking you off your target. I only realised [during the campaign] how toxic Twitter was, I knew it was toxic, but I didn't realise how toxic it was.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Examiner
2 hours ago
- Irish Examiner
Nato set to approve new military purchases as part of a defence spending hike
Nato defence ministers are set to approve purchasing targets for stocking up on weapons and military equipment to better defend Europe, the Arctic and the North Atlantic, as part of a US push to ramp up security spending. The 'capability targets' lay out goals for each of the 32 nations to purchase priority equipment such as air defence systems, long-range missiles, artillery, ammunition, drones and 'strategic enablers' such as air-to-air refuelling, heavy air transport and logistics. Each nation's plan is classified, so details are scarce. 'Today we decide on the capability targets. From there, we will assess the gaps we have, not only to be able to defend ourselves today, but also three, five, seven years from now,' Nato Secretary-General Mark Rutte said. 'All these investments have to be financed,' he told reporters before chairing the meeting at Nato's Brussels headquarters. US Defence Secretary Pete Hegseth delivers a statement ahead of the meeting at Nato headquarters in Brussels on Thursday (Virginia Mayo/AP) US President Donald Trump and his Nato counterparts will meet on June 24-25 to agree to new defence investment goals. US Defence Secretary Pete Hegseth said that 'to be an alliance, you've got to be more than flags. You got to be more than conferences. You need to keep combat ready capabilities'. Spurred on by their own security concerns, European allies and Canada have already been ramping up military spending, including arms and ammunition purchases, since Russia launched a full-scale invasion of Ukraine in 2022. At the same time, some allies balk at US demands to invest 5% of their gross domestic product in defence – 3.5% on core military spending and 1.5% on the roads, bridges, airfields and sea ports needed to deploy armies more quickly – when they have already struggled to grow their budgets to 2% of GDP. The new targets are assigned by Nato based on a blueprint agreed upon in 2023 – the military organisation's biggest planning shake-up since the Cold War — to defend its territory from an attack by Russia or another major adversary. Under those plans, Nato would aim to have up to 300,000 troops ready to move to its eastern flank within 30 days, although experts suggest the allies would struggle to muster those kinds of numbers. The member countries are assigned roles in defending Nato territory across three major zones – the high north and Atlantic area, a zone north of the Alps, and another in southern Europe. Are we going to gather here again and say 'OK, we failed a bit', and then maybe we start learning Russian? Nato planners believe that the targets must be met within five to 10 years, given the speed at which Russia is building its armed forces now, and which would accelerate were any peace agreement reached to end its war on Ukraine. Some fear Russia might be ready to strike at a Nato country even sooner, especially if Western sanctions are eased and Europe has not prepared. 'Are we going to gather here again and say 'OK, we failed a bit', and then maybe we start learning Russian?' Lithuanian Defence Minister Dovile Sakaliene said. Swedish Defence Minister Pal Jonson also warned that while Russia is bogged down in Ukraine right now, things could quickly change. 'We also know after an armistice or a peace agreement, of course, Russia is going to allocate more forces closer to our vicinity. Therefore, it's extremely important that the alliance use these couple of years now when Russia is still limited by its force posture in and around Ukraine,' Mr Jonson said. If the targets are respected, the member countries will need to spend at least 3% of GDP on defence. Dutch Defense Minister Ruben Brekelmans said his country calculates in the medium term that 'we should spend 3.5% at least on defence, which in the Netherlands means an additional 16 to 19 billion euro (£13-16 billion) addition to our current budget.' The Netherlands is likely to buy more tanks, infantry fighting vehicles and long-range missile systems, including US-made Patriots that can target aircraft, cruise missiles and shorter-range ballistic missiles.
The Journal
4 hours ago
- The Journal
European Central Bank expected to cut interest rates later today
THE EUROPEAN CENTRAL Bank is expected to cut interest rates by a quarter of a percentage point today. It would be the bank's eighth interest rate cut in the last 12 months, with officials having shifted focus from taming consumer price rises to easing pressure on the sluggish eurozone economy. Expectations that the Frankfurt-based institution will deliver a fresh rate cut were strengthened this week when data showed eurozone inflation eased to 1.9% in May, faster than expected and below its 2% target. 'Any doubts about an ECB interest rate cut this week have now been eliminated,' said Dirk Schumacher, chief economist at German public lender KfW. Advertisement Analysts expect another quarter-point reduction that would take the central bank's key deposit rate to 2%. The reduction would be welcome news for tracker mortgage holders, who would benefit immediately from the move, along with other borrowers. Despite falling ECB rates, Ireland is the fifth most expensive country in the eurozone for mortgages, with Irish homebuyers paying 0.46 percentage points more than the average interest rate on new mortgages across the euro zone, according to a recent Central Bank report. Observers will be on the lookout for any hints from ECB President Christine Lagarde at her press conference that policymakers could hit pause at their next meeting in July, as some expect. The ECB's series of cuts stands in contrast to the US Federal Reserve, which has kept rates on hold recently amid fears that Trump's levies could stoke inflation in the world's top economy. With reporting from © AFP 2025 Readers like you are keeping these stories free for everyone... A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation. Learn More Support The Journal
RTÉ News
6 hours ago
- RTÉ News
Bitter pill: EU exploits Trump anti-science climate to forge deal on medicines
The EU's sweeping new rules on the regulation of medicines has been one of the most bitterly contested pieces of legislation in recent times, with fierce lobbying by the pharma sector - particularly in Ireland - and member states divided on which to prioritise: cheaper medicines for patients, or a regulatory environment that supports indigenous European manufacturers in the face of US dominance. After two years of deadlock, 26 member states have agreed on a compromise proposal, with only Malta - which has its own small-market medicines challenge - abstaining. Ironically, it was the Trump administration's hostility to science and medicine regulators that convinced EU member states that the moment to finally agree on a new set of rules was at hand. "In the US you have a chaotic situation," says one source familiar with negotiations, "between [Health Secretary] Robert Kennedy Jr, who doesn't believe in science or vaccines, and the Trump administration, which has sacked three and a half thousand people from the Food and Drugs Administration. "There was a sense in Europe that we should try to get this proposal settled so that we have a stable system in Europe when there's instability elsewhere." The legislation will now go to the European Parliament, where negotiations between MEPs, the member states and the European Commission, begin on 17 June. There are hopes that the entire package could be adopted by the end of the year. The European Commission first proposed overhauling the EU's medicines regime in April 2023, as Europe was emerging from the Covid pandemic. The EU was reeling from the strain the emergency put on health systems and on the availability of certain kinds of medicines, with a deepening awareness that Europe was overly dependent on China and India for drugs such as antibiotics. At the same time, digitalisation and the availability of clinical data were opening up new possibilities in how medicines are developed and used. Despite that, innovative therapies were not reaching patients across Europe at the same speed while in some member states patients did not have access to medicines they needed due to shortages. The instinct to reduce health spending further has been given fresh impetus by the expected surge in EU defence expenditure following Russia's invasion of Ukraine. Overall, the pharma package sought to boost the competitiveness of the sector, reduce the administrative burden - and the over-reliance on India and China - and to tackle the environmental impact of drug manufacture and use. The central, most divisive issue was around the protection that big European pharma countries would have in holding on to clinical data before generic manufacturers - who could produce cheaper drugs - could access it. It became a straightforward contest between the competing interests of big pharma, which argued that companies needed the protection in order to invest more in life-saving domestic European research and innovation, and those countries which were more interested in lowering the cost of medicines and making those medicines more accessible to patients. The legislation was always going to face a stormy passage. "The difficulty was that the countries that didn't have pharmaceutical industries were very much opposing the regulatory data protection (RDP) element because all they were interested in was making medicines available to citizens," says Fianna Fáil MEP Billy Kelleher, a substitute member of the European Parliament health committee. "Eastern European countries like Poland, Romania, Bulgaria and others would have been very, very reluctant to support the strong protection of regulatory data, while it was the old West, countries like Ireland, Belgium, Italy, Germany and the Netherlands that have big manufacturing and pharma centres, a lot of research and development, who were pushing for it." The new rules would attempt to reconcile the issue of regulatory data protection, which theoretically encourages pharmaceutical companies to invest more in life-saving medicines, with the need to make drugs more affordable. Under existing EU rules, pharma companies were entitled to keep clinical data for eight years - the so-called regulatory data protection (RDP) before they were obliged to make it accessible. After the eight years was up, generic producers could file an application to use the data, at which point the patent holder enjoyed a further two - and sometimes three - extra years of protection. Under the commission's 2023 proposal, there would be a two-year reduction in the baseline RDP to six years, with an extra two years of protection. However, pharma companies could claw back a further two years of protection - extending RDP to ten years. The ten-year protection period would be available if the patent holder won approval for significant new innovations (one extra year of protection), if the product addressed an "unmet medical need", ie, where there was product authorised in the EU for a particular disease, or where the disease was associated with a high death-rate (such a situation would merit an extra six months of market protection), or if the manufacturer conducted clinical trials or extended access to all member states (another six months). Essentially, the commission was attempting to balance the need to reward medicines that meet the greatest clinical need, while speeding up access to generic producers who will make drugs that are cheaper. However, the new rules were facing hostility from traditional pharma manufacturing countries such as Germany, France, Denmark and the Netherlands, who argued that a shorter clinical data protection period would stymie research. The Irish Times reported on a full scale lobbying effort by industry, including a claim in a letter to Tánaiste Simon Harris by the Irish Pharmaceutical Healthcare Association (IPHA) that the proposal could lead to a 22% drop in new medicines being developed over the coming decade. It is understood there were tensions between the IDA and Enterprise Ireland, who shared the concerns of industry, and the Department of Health, which was more concerned with lowering the cost of medicines and making them more accessible. A number of sources have said that while member states with important pharma sectors went public two years ago, when the commission first proposed reducing clinical data protection from eight years to six, in demanding the status quo of eight years, Ireland remained on the fence, and did so right up until a key meeting of EU ambassadors on 21 May. On that date, Ireland joined a blocking majority of ten countries - including Belgium, Denmark, the Netherlands and Germany - to oppose the latest Polish proposal that would have essentially increased the RDP by one year to seven, but short of eight. As a result of that blocking minority, the Poles came back with another compromise text, which is - to all intents and purposes - a return to eight years, with various caveats and conditions designed to make medicines cheaper and more accessible (one part of the text aims to ensure that medicinal products are available in all member states and provides for regulatory action if the marketing authorisation holder does not comply). Officials say the text provides more reassurance for generic producers, and will cut timelines for authorised medicines to get to market. There are other measures, including making it easier to have multi-country and multilingual medicine packs, which should reduce production costs and make it easier to move medicines around Europe. At yesterday morning's meeting of EU ambassadors, the new text received overwhelming support. The IPHA are understood to be broadly satisfied with the compromise. In a statement, the organisation said it "believes the [member states] position represents a more balanced approach than had originally been proposed by the Commission. "As the legislative process enters the final phase, EU decision makers must continue to find solutions that will keep Europe competitive through a predictable and globally competitive environment for research, development and manufacturing, while ensuring fairer access to innovative medicines for patients across the EU." Support is not uniform. The chief executive of the Confederation of Danish Industry Lars Sandahl Sørensen accused member states of triggering a potential flight of European industry to Trump's America. "We are de facto making the EU's pharmaceutical industry less competitive and thus European society vulnerable," he said. The European pharma lobby group EFPIA described yesterday's position by member states as "a missed opportunity to position Europe's life sciences sector at the forefront of global competition". In a statement, EFPIA said: "The choice to reduce intellectual property protections for pharmaceutical companies makes Europe less attractive, discouraging investment and jeopardising the development of innovative treatments in Europe without addressing the underlying barriers and delays to patient access." There is some scepticism over the industry's seeming exploitation of Donald Trump's persistence in threatening tariffs on European pharmaceutical exports and reshoring manufacturing to the US. In April the industry wrote to commission president Ursula von der Leyen, suggesting that €50.6 billion in capital investment and €52.6bn in research and development expenditure were at risk if the EU continued to over-regulate the pharma sector. "Unless Europe delivers rapid, radical policy change then pharmaceutical research, development and manufacturing is increasingly likely to be directed towards the US," EFPIA warned. Officials suggest the upcoming Critical Medicines Act (CMA) will further boost access to cheaper medicines. Drugs such as those for diabetes or HRT have been susceptible to disruption and shortages in recent years because they are often generic and produced outside the EU. The CMA will aim to encourage more manufacturing of such drugs in Europe. The action now moves to the European Parliament, where so-called trilogues - three way negotiations between member states, the Commission and MEPs - will further shape the legislation. Last year the parliament adopted its own position, calling for an RDP of seven and a half years with the possibility of some extensions. The parliament has since moved to the right, following last year's elections, so it remains to be seen if further battles are expected.
